



Epizyme Launches In My Blood Online Resource to Empower People Living with Follicular Lymphoma to Play a Proactive Role in Treatment-Decision Making

November 1, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 1, 2021-- Epizyme today announced the launch of *In My Blood*, an online resource designed to empower people living with follicular lymphoma to partner with their healthcare providers and play a proactive role in treatment decision-making based on where they are in their follicular lymphoma journey.

This press release features multimedia. View the full release here: <https://www.businesswire.com/news/home/20211101005113/en/>



'In My Blood' logo

their healthcare providers. The personalized guide is designed for patients at any stage of their experience with follicular lymphoma and provides tools for them to engage proactively in their health, during both periods of treatment and remission.

"Over the years, through continued partnership with healthcare providers and patient advocates in the follicular lymphoma community, we've seen firsthand the importance of the healthcare provider-patient relationship when dealing with the complexities of navigating this typically incurable blood cancer over many years, sometimes even decades," said Cheya Pope, Vice President, Corporate Affairs at Epizyme. "Knowing this relationship is paramount, we created *In My Blood* and *My Follicular Lymphoma Coach*, with input from the follicular lymphoma advocacy community, to fulfill a need for patients. We hope the resources provided will enable meaningful conversations between patients and healthcare providers to ultimately improve care."

As clear and proactive communication with healthcare providers is essential in order to detect signs of a potential relapse in follicular lymphoma, *In My Blood* also offers downloadable daily and weekly symptom trackers to support patients and care partners with disease monitoring. It also features stories and insights from individuals living with follicular lymphoma, which highlight how they have been able to proactively manage their disease and celebrates how they continue living life to the fullest. Additional resources, background information and links to related advocacy organization resources are also available.

"Upon learning you have follicular lymphoma the sheer volume of information, choices, and decisions you have to make can feel overwhelming. When I was newly diagnosed, I knew that I would need to advocate for myself to ensure that I received the best care and treatment based on my diagnosis and individual needs," said Kendra Munger, *In My Blood* patient ambassador. "Now with *In My Blood* and *My Follicular Lymphoma Coach*, patients like me who are navigating life with follicular lymphoma can create a personalized guide with relevant information for where they are in their follicular lymphoma journey, along with important questions to ask their doctors as they work together to determine the best path forward."

For more information on *In My Blood* and to access *My Follicular Lymphoma Coach*, visit [FollicularLymphoma.com](https://www.follicularlymphoma.com).

About Follicular Lymphoma

Follicular lymphoma is a type of cancer that starts in the lymphatic system, a system of lymph nodes found throughout the body.ⁱ Of the estimated 74,000 individuals diagnosed with non-Hodgkin's lymphoma in the United States each year, follicular lymphoma accounts for approximately 20% of all cases, or about 14,800 individuals.ⁱⁱ People with follicular lymphoma often experience periods of remission before the disease returns (relapse), and they typically undergo treatment with numerous therapies during their disease journey. In addition, many patients find their cancer has become resistant to treatments they've received before, leaving them with fewer options when their cancer returns. To learn more about follicular lymphoma and *In My Blood*, visit [FollicularLymphoma.com](https://www.follicularlymphoma.com).

About Epizyme, Inc.

Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. The Company is focused on creating medicines that are targeted at specific causes of diseases,

In My Blood offers follicular lymphoma patients, and their care partners, unique resources to aid them in taking a proactive role in their care as they navigate life with this typically incurable blood cancer. A central feature is *My Follicular Lymphoma Coach*, a first-of-its-kind quiz for follicular lymphoma patients. This brief questionnaire takes key information into consideration, including stage of disease, current symptoms, and lifestyle. Patients are then provided with a customized, downloadable guide to support them in having proactive, informed discussions with

that are orally administered, tolerable, easy to take and based on a deep understanding of the patients that may benefit from them. The Company aspires to change the standard-of-care for patients and physicians by developing medicines with fundamentally new mechanisms of action. For more information, visit www.epizyme.com.

ⁱ Lymphoma- Non-Hodgkin: Introduction. Cancer.Net. Accessed April 15, 2020. Available at: <https://www.cancer.net/cancer-types/lymphoma-non-hodgkin/introduction>

ⁱⁱ About Non-Hodgkin Lymphoma. American Cancer Society. Accessed April 15, 2020. Available at: <https://www.cancer.org/cancer/non-hodgkin-lymphoma/about.html>

View source version on businesswire.com: <https://www.businesswire.com/news/home/20211101005113/en/>

Media:

Erin Graves
media@epizyme.com
(617) 500-0615

Investors:

Craig West
cwest@epizyme.com
(857) 270-6001

Source: Epizyme, Inc.